Integrated BioPharma, Inc. · OTC:INBP
Integrated BioPharma — Investor Presentation (June 2005)
12 slides from Integrated BioPharma's investor presentation, Jun 13, 2005
Slide 1: Investor Presentation June 2005
Exhibit 99.1 Investor Presentation June 2005 =================================== 80 Years of Commitment to Health Safe Harbor Statement Statements contained in this presentation, which are not historical facts, are forward looking statements, as the term is defined in the Private Securities Litigati
Slide 2: Vision, Corporate Snapshot and Organizational Structure
Vision We aspire to become a world class, fully integrated biopharmaceutical company, capable of the full spectrum of discovery of new compounds, clinical trials, manufacturing, and marketing these products, while continuing to grow and harvest cash flows from our expanding nutraceutical businesses,
Slide 3: Biopharma Pipeline
o Effective isolation technologies oSpecific products - Vaccines - Therapeutic proteins, including monoclonal antibodies and human growth hormone 6 Biopharma Pipeline Project Product Target Current Status Milestones Pre-clinicals Bacillus anthracis AV154 Oral Anthrax vaccine Anticipated human clinic
Slide 4: Nutraceuticals and Technology Licenses
Nutraceuticals o AgroLabs, Inc. markets and distributes the Naturally Aloe, Naturally Noni, and Avera Sport; most recent growth driver for InB o Manhattan Drug Company manufactures and sells nutritional supplements including vitamins, minerals and herbal products o Three other subsidiaries - sell an
Slide 5: Intellectual Property and Goals FY2006
13 Intellectual Property Protein Expression, Ongoing Filings o Rapid production - Flu (compositions and methods) o Multifaceted production (activated clonal, optionally fused) - hGH - Various antibodies o Antibody production o Oral hGH application (first provisional filed) 14 Intellectual Property N
Slide 6: Progress Toward Goals
17 Progress Toward Goals We aspire to become a world class, fully integrated biopharmaceutical company, capable of the full spectrum of discovery of new compounds, clinical trials, manufacturing, and marketing these products, while continuing to grow and harvest cash flows from our expanding nutrace
Slide 7: Markets: Market size and growth
Fiscal Years 21 Markets Market size o Pharmaceuticals 2004 $550 billion1 (WW) o Cancer therapy 2004 $42 billion1 (WW) o Nutraceuticals $19.8 billion2 (US) Market growth o Pharmaceuticals 7 - 10% worldwide through 20081 (WW) o Cancer therapy over 25% through 20051 (WW) o Nutraceuticals average growth
Slide 8: Markets: Pharmaceuticals and Cancer Therapeutics
Pharmaceuticals - $550 billion in 2004; growing at 7 - 10% worldwide through 2008* *MedAdNews, IMS Health 23 Markets Cancer therapeutics - $42 billion in 2004; average annual growth over 25% during next five years*
Slide 9: Markets: Nutraceuticals
* MedAdNews 24 Markets Nutraceuticals - $19.8 billion in 2003; growing at average of 4.2% through 2009*
Slide 10: Senior Management and Board of Directors
*Nutrition Business Journal 25 Senior Management E. Gerald Kay, CEO and Chairman Gregory A. Gould, CFO and Senior VP Seymour Flug, Senior Advisor Robert B. Kay, Chairman, InB:Paxis Eric Friedman, CEO, AgroLabs, Senior VP, InB Orn Adalsteinsson, President, InB:Biotechnologies Geoffrey Schild, CSO, In
Slide 11: Board and Scientific Advisory Board
Carl DeSantis, President, CDS International Holdings, Inc. Glenn Chang, CFO, First American International Bank Zarko Kraljevic, CEO, Diners Club of Eastern Europe Riva Kay Sheppard, Vice President, Sales and Marketing, InB Christina Kay, Vice President, Logistics, InB 27 Scientific Advisory Board Or
Slide 12: Why Integrated BioPharma?
We have a strong platform for growth: o People o Vision o Processes o Technology o Opportunity Focused on return to profitability 30
Integrated Biopharma — Investor Presentation (June 2005) on 6ix